https://mindmedicinelaw.com/briefing/phmsa-s-proposed-hazmat-rule-impacts-on-psychedelic-research-supply-chains-20261027-54106The Psychedelic Journalen2026-10-27T15:05:30.039363+00:00PHMSA’s Proposed Hazmat Rule: Impacts on Psychedelic Research Supply Chainsphmsa, hazardous materials regulations, psychedelic research, international harmonization, chemical shipping, regulatory compliance, clinical trial logistics, federal register, supply chain riskhttps://mindmedicinelaw.com/briefing/media-coverage-of-psilocybin-outpaces-science-systematic-review-insights-20261027-54241The Psychedelic Journalen2026-10-27T15:05:14.437839+00:00Media Coverage of Psilocybin Outpaces Science: Systematic Review Insightspsilocybin media coverage, systematic review 2026, science communication, psychedelic policy, clinical trial reporting, public health risk, regulatory approval, hype in medicine, patient expectationshttps://mindmedicinelaw.com/briefing/australian-ketamine-trial-targets-emergency-worker-mental-health-20261027-54242The Psychedelic Journalen2026-10-27T15:04:55.410952+00:00Australian Ketamine Trial Targets Emergency Worker Mental Healthketamine trial australia, emergency service workers mental health, ptsd depression treatment, black dog institute research, psychedelic-assisted therapy, australian clinical trials, tga regulation, occupational mental health, ketamine safety riskshttps://mindmedicinelaw.com/briefing/5-meo-dmt-from-toad-venom-clinical-trial-for-depression-in-2026-20261026-54065The Psychedelic Journalen2026-10-26T22:06:21.323921+00:005-MeO-DMT From Toad Venom: Clinical Trial for Depression in 20265-meo-dmt, toad venom, treatment-resistant depression, psychedelic clinical trials, fda guidance, psychiatric research, synthetic vs natural psychedelics, schedule i substances, ecological impact, psychedelic regulationhttps://mindmedicinelaw.com/briefing/oregon-s-psilocybin-therapy-program-first-real-world-study-findings-20261026-54066The Psychedelic Journalen2026-10-26T22:06:01.559772+00:00Oregon’s Psilocybin Therapy Program: First Real-World Study Findingspsilocybin therapy, oregon health authority, psychedelic regulation, real-world evidence, mental health policy, facilitator training, adverse events, access disparities, clinical outcomes, state-level legalizationhttps://mindmedicinelaw.com/briefing/fda-leadership-issues-formal-policy-statement-on-psychedelics-20261026-54064The Psychedelic Journalen2026-10-26T22:05:42.070780+00:00FDA Leadership Issues Formal Policy Statement on Psychedelicsfda psychedelics policy, psychedelic drug approval, clinical trial design, therapist training requirements, regulatory risk, real-world evidence, psychedelic industry, post-marketing surveillance, mental health therapieshttps://mindmedicinelaw.com/briefing/self-compassion-in-mdma-assisted-therapy-for-social-anxiety-early-clinical-insig-20261025-53969The Psychedelic Journalen2026-10-26T22:06:38.826737+00:00Self-Compassion in MDMA-Assisted Therapy for Social Anxiety: Early Clinical Insightsmdma-assisted therapy, self-compassion, social anxiety disorder, psychedelic clinical trials, mechanisms of action, internalized shame, depressive symptoms, treatment moderators, trial design, psychological mechanismshttps://mindmedicinelaw.com/briefing/israel-s-national-mdma-and-psilocybin-ptsd-trial-scope-and-implications-20261025-53890The Psychedelic Journalen2026-10-25T22:04:47.335672+00:00Israel’s National MDMA and Psilocybin PTSD Trial: Scope and Implicationsisrael, mdma, psilocybin, ptsd, clinical trial, psychedelic research, government policy, international, mental health, regulatoryhttps://mindmedicinelaw.com/briefing/esketamine-use-and-postoperative-mental-health-in-elderly-chinese-patients-20261024-53997The Psychedelic Journalen2026-10-26T22:07:33.030878+00:00Esketamine Use and Postoperative Mental Health in Elderly Chinese Patientsesketamine, postoperative anxiety, postoperative depression, elderly patients, china, perioperative mental health, nmda antagonist, clinical trials, psychedelic research, public healthhttps://mindmedicinelaw.com/briefing/muscarinic-signaling-and-prefrontal-stm-implications-for-neuropsychiatric-drug-d-20261024-53996The Psychedelic Journalen2026-10-26T22:07:12.648937+00:00Muscarinic Signaling and Prefrontal STM: Implications for Neuropsychiatric Drug Developmentmuscarinic signaling, prefrontal cortex, short-term memory, thalamic drive, acetylcholine, neuropsychiatric therapeutics, cognitive enhancement, mechanistic neuroscience, psychedelic drug development, clinical trial designhttps://mindmedicinelaw.com/briefing/validated-recovery-curves-for-phq-8-and-gad-7-in-outpatient-care-20261024-53998The Psychedelic Journalen2026-10-26T22:06:56.508249+00:00Validated Recovery Curves for PHQ-8 and GAD-7 in Outpatient Caremeasurement-based care, phq-8, gad-7, recovery curves, psychedelic clinical trials, outpatient mental health, treatment failure prediction, depression endpoints, anxiety endpointshttps://mindmedicinelaw.com/briefing/ketamine-integration-in-emergency-care-evidence-from-2026-review-20261018-53881The Psychedelic Journalen2026-10-25T22:04:59.512028+00:00Ketamine Integration in Emergency Care: Evidence from 2026 Reviewketamine, emergency care, clinical protocols, acute pain management, sedation, policy implications, hospital guidelines, safety considerations, opioid alternatives